Documentation of the effect of an direct or overlapping switch from another dopamine agonist to Sifrol® on motor function, psychopathological disturbances and mood, assessment of the reasons for the switch and the reasons for using Sifrol®, equivalent doses at the end of the switch and tolerability of Sifrol® in ambulatory patients suffering from idiopathic Parkinson's disease under routine conditions
Study Type
OBSERVATIONAL
Enrollment
1,216
Reason for switch of therapy and reason for using Sifrol®
questionnaire
Time frame: up to 8 weeks
Type of switch (abrupt or overlapping)
Time frame: up to 8 weeks
Changes in motor function by means of 5-points rating scale
Short Parkinson's Evaluation Scale (SPES)
Time frame: up to 8 weeks
Changes in psychopathological memory disturbances by means of 5- point rating scale
Short Parkinson's Evaluation Scale (SPES)
Time frame: up to 8 weeks
Changes in psychopathological thought disorder disturbances by means of 5- point rating scale
SPES score
Time frame: up to 8 weeks
Changes in psychopathological depression disturbances by means of 5- point rating scale
SPES score
Time frame: up to 8 weeks
Changes of mood on seven visual analogue scales (VASs)
assessed by patient
Time frame: up to 8 weeks
Equivalent doses of Sifrol®
compared to previous treatment dosing, based on global clinical impression
Time frame: after 8 weeks
Global assessment of efficacy by investigator on a 5-point rating scale
Time frame: after 8 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Number of patients with adverse drug reactions
Time frame: up to 8 weeks
Assessment of tolerability by investigator on a 5-point rating scale
Time frame: after 8 weeks